According to Fintel, on September 18, 2023, HC Wainwright & Co. reiterated its Buy recommendation for Alnylam Pharmaceuticals (NASDAQ:ALNY).
Analyst Price Forecast Shows 39.85% Upside
As of August 31, 2023, the average one-year price target for Alnylam Pharmaceuticals is $251.40. The range of forecasts is between $142.41 and $425.25. The average price target represents a 39.85% increase from the latest reported closing price of $179.77.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Alnylam Pharmaceuticals is $1,521 million, an increase of 22.92%. The projected annual non-GAAP EPS is -$5.74.
What is the Fund Sentiment?
There are 1,005 funds or institutions reporting positions in Alnylam Pharmaceuticals. This is a decrease of 31 owners or 2.99% in the last quarter. The average portfolio weight of all funds dedicated to ALNY is 0.32%, a decrease of 12.09%. Total shares owned by institutions decreased in the last three months by 0.00% to 144,825,000 shares.
The put/call ratio of ALNY is 1.31, indicating a bearish outlook.
What are Other Shareholders Doing?
Capital World Investors holds 16,498,000 shares representing 13.20% ownership of the company. In its prior filing, the firm reported owning 16,476,000 shares, representing an increase of 0.13%. The firm decreased its portfolio allocation in ALNY by 11.65% over the last quarter.
Baillie Gifford holds 8,392,000 shares representing 6.71% ownership of the company. In its prior filing, the firm reported owning 8,639,000 shares, representing a decrease of 2.94%. The firm increased its portfolio allocation in ALNY by 132.52% over the last quarter.
AGTHX – GROWTH FUND OF AMERICA holds 7,929,000 shares representing 6.34% ownership of the company. In its prior filing, the firm reported owning 7,572,000 shares, representing an increase of 4.50%. The firm decreased its portfolio allocation in ALNY by 3.93% over the last quarter.
Wellington Management Group Llp holds 6,068,000 shares representing 4.85% ownership of the company. In its prior filing, the firm reported owning 6,154,000 shares, representing a decrease of 1.42%. The firm decreased its portfolio allocation in ALNY by 10.78% over the last quarter.
VGHCX – Vanguard Health Care Fund Investor Shares holds 4,719,000 shares representing 3.77% ownership of the company. No change in the last quarter.
Alnylam Pharmaceuticals Background Information
(This description is provided by the company.)
Alnylam Pharmaceuticals Inc. is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its ‘Alnylam P5x25’ strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
